arGentis Pharmaceuticals, LLC has selected Target Health, Inc. as its Clinical Research Organization (CRO) partner for their upcoming clinical trials. With clinical trial costs increasing dramatically, it has been demonstrated that the selection of a quality CRO provides cost saving opportunities for their drug sponsors. Utilizing Target Health’s global expertise across multiple therapeutic categories will allow arGentis to expand development capacity without requiring an increase in staff or facilities.
“This alliance delivers us immediate speed and efficiency to our drug development efforts resulting in quality clinical trial data at high levels of regulatory compliance,” stated Tom Davis, arGentis’ Chief Executive Officer. “Target Health’s proven track record of NDA and PMA approvals verifies that we will be able to accrue valuable clinical study performance through enhanced planning and achieve favorable end points to our trials.”
According to Dr. Jules T. Mitchel, President of Target Health Inc., “We are pleased to have been chosen by arGentis as their CRO partner to facilitate their forthcoming clinical trials. Their product therapies fit well with our expertise and are in areas of unmet medical needs. We look forward to working with the arGentis management team along with their scientific advisors toward advancing their platforms for FDA review.”
arGentis licensed two transdermal therapies for the treatment of dry eye syndrome (DES) from the Southern College of Optometry in 2006. The company plans to submit an Investigational New Drug application to the FDA on both products in the fourth quarter of 2007. Target Health will assist in this filing and provide all regulatory and quality deliverables throughout the clinical trial process.
arGentis Pharmaceuticals, LLC is a specialty pharmaceutical company located in Memphis, TN. The company seeks to in-license therapies for chronic diseases with demonstrated proof of concept for further development and commercialization.